Coordinate in vivo gene expression

Details Coordinate in vivo gene expression Coordinate in vivo gene expression

2006-02-07

2006-02-07

Guzo, David (Department: 1636)

Chemistry: molecular biology and microbiology

Vector, per se

C536S023100, C536S023500, C536S023720, C536S024100

Reexamination Certificate

active

06995008

ABSTRACT:
Nucleic acids, including DNA constructs and RNA transcripts, capable of inducing coordinate expression of two to three cistrons upon direct introduction into animal tissues, are bi- or tri-cistronic polynucleotides of this invention include those encoding and co-expressing HIV gene products, genes encoding antigens unrelated to HIV, and immunostimulatory gene products, including but not limited to GM-CSF, interleukins, interferon and members of the B7 family of proteins which act as T-cell costimulatory elements. The methods and polynucleotides of this invention are generally applicable to co-ordinate expression in vivo of any two or more genes in a single cell.

REFERENCES:
patent: 3931397 (1976-01-01), Harnden
patent: 4124702 (1978-11-01), Lampson et al.
patent: 4224404 (1980-09-01), Viza et al.
patent: 4394448 (1983-07-01), Szoka, Jr. et al.
patent: 4396601 (1983-08-01), Salser et al.
patent: 4405712 (1983-09-01), Vande Woude et al.
patent: 4689320 (1987-08-01), Kaji
patent: 4806463 (1989-02-01), Goodchild et al.
patent: 4897355 (1990-01-01), Eppstein et al.
patent: 4937190 (1990-06-01), Palmenberg et al.
patent: 4946787 (1990-08-01), Eppstein et al.
patent: 5036006 (1991-07-01), Sanford et al.
patent: 5049386 (1991-09-01), Eppstein et al.
patent: 5168062 (1992-12-01), Stinski
patent: 5208036 (1993-05-01), Eppstein et al.
patent: 5256553 (1993-10-01), Overell
patent: 5298422 (1994-03-01), Schwartz et al.
patent: 5674703 (1997-10-01), Woo et al.
patent: 5736524 (1998-04-01), Content et al.
patent: 5861290 (1999-01-01), Goldsmith et al.
patent: 5866553 (1999-02-01), Donnelly et al.
patent: 6107062 (2000-08-01), Hu et al.
patent: 6228844 (2001-05-01), Wolff et al.
patent: 0 187 702 (1986-07-01), None
patent: 0 187 702 (1986-07-01), None
patent: 0 585 983 (1993-07-01), None
patent: WO 86/00930 (1986-02-01), None
patent: WO 90/01543 (1990-02-01), None
patent: WO 90/11092 (1990-10-01), None
patent: WO 91/00359 (1991-01-01), None
patent: WO 91/07487 (1991-05-01), None
patent: WO 91/16024 (1991-10-01), None
patent: WO 91/17424 (1991-11-01), None
patent: WO 93/03143 (1993-02-01), None
patent: WO 93/03709 (1993-03-01), None
patent: WO 93/11250 (1993-06-01), None
patent: WO 93/12240 (1993-06-01), None
patent: WO93/12756 (1993-07-01), None
patent: WO 93/17706 (1993-09-01), None
patent: WO 93/20212 (1993-10-01), None
patent: WO 93/19768 (1993-11-01), None
patent: WO93/11250 (1993-12-01), None
patent: WO 93/24640 (1993-12-01), None
patent: WO 94/04196 (1994-03-01), None
Haynes, Scientific and Social Issues of HIV . . . , Science vol. 260, pp. 1279-1285, May 1993.
Schwartz et al, Expression of HIV-1 vif and vpr mRNAs is REV dependent . . . , vol. 183, pp.677-86, Aug. 1991.
Smarda et al, Dicistronic selection for nuclear proteins in living animal cells, Gene vol. 137, pp.145-149, Dec. 1993.
Ulmer et al., Heterologous Protection against Influenza by injection of DNA encoding a viral protein, Science vol. 259, 1745-49, Mar. 1993.
Petit, “Antibodies That Fight AIDS Can Also Incite It, Report Says”, San Francisco Chronicle, (Dec. 15, 1993).
Robinson et al., Protection Against a Lethal Influenza Virus Challenge by Immunization with a Haemagglutinin-Epxressing Plasmid DNA, Vac., vol. 11, Issue 9, pp. 957-960 (1993).
Petricciani, “Global Immunization Against AIDS, Economic Considerations”, Vac., vol. 11, Issue 8, pp. 873-877 (1993).
Burke, et al., “Vaccine Therapy for HIV: A Historical Review of the Treatment of Infectous Diseases by Active Specific Immunization . . . ”, Vac., vol. 11, Issue 9, pp. 883-891 (1990).
Troni, et al., “HIV-1 Gag Mutants Can Dominantly Interfere with the Replication of the Wild-Type Virus”, Cell, vol. 59, pp. 113-120 (Oct. 6, 1989).
Kobayashi, et al., “Identification and Purification of Natural Killer Cell Stimulatory Factor (NKSF), A Cytokine with Multiple Biologic . . . ”, J. Exp. Med., vol. 170, pp. 827-845 (Sep. 1989).
Stern, et al., “Purification to Homogeneity and Partial Characterization of Cytotoxic Lymphocyte Maturation Factor from Human B-Lymphoblastoid Cells”, Proc. Natl. Acad. Sci., Imm., vol. 87, pp. 6808-6812 (Sep. 1990).
Afonso, et al., “Adjuvant Effect of Interleukin-12 in a Vaccine Against Leishmania major”, Sci., vol. 263, pp. 235-237, (Jan. 14, 1994).
Townsend & Allison, “Tumor Rejection After Direct Stimulation of CD8+T Cells by B7-Transfected Melanoma Cells”, Sci., vol. 259, pp. 368-270 (Jan. 15, 1993).
Gimmi, et al., “B-cell surfact antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2”, Proc. Natl. Acad. Sci. USA, Imm., vol. 88, pp. 6575-6579 (Aug. 1991).
Freeman, et al., “B7, A New Member of the Ig Superfamily with Unique Expression on Activated and Neoplastic B Cells”, J. Immunology, vol. 143, pp. 2714-2722, No. 8, (Oct. 15, 1989).
Edginiton, “Turning On Tumor-Fighting T-Cells”, Bio/Tech., vol. 11, pp. 1117-1119 (Nov. 10, 1993).
Calin-Laurens, et al., “Can one predict antigenic peptides for MHC class I-restricted cytotoxic T lymphocytes useful for vaccination?”, Vac., vol. 11, Issue 9, pp. 944-978.
Eriksson, et al., “Systematic identification of T-cell activating epotopes on the human immunodeficieicy virus type 1 envelope glcoprotein gp120 in primates immunized with synthetic peptides”, Vac., vol. 11, Issue 8, pp. 859-8865.
Berzofsky, et al., “Construction of Peptides Encompassing Multideterminant Clusters of Human Immunodeficiency Virus Envelope to Induce in Vitro T Cell”, J. Clin. Inves., Inc., vol. 88, pp. 876-884 (Sep. 1991).
Choppin, et al., “HLA-Binding Regions of HIV-1 Proteins”, J. Immunology, vol. 147, No. 2, pp. 575-583 (Jul. 15, 1991).
Choppin, et al., “HLA—Binding Regions of HIV-1 Proteins”, J. Innunology, vol. 147, No. 2, pp. 569-574 (Jul. 15, 1991).
Tsuliyama, et al., “Internal Ribosome Entry Site within Hepatitis C Virus RNA”, J. Virology, vol. 66, No. 3, pp. 1476-1483 (Mar. 1992).
Shirai, et al., “Broad Recongnition of Cytotoxic T Cell Epitopes from the HIV-1 Envelope Protein with Multiple Class I Histocompatibility . . . ”, J. Immunology, vol. 148, No. 6, pp. 1657-1667 (Mar. 15, 1992).
Gheysen, et al., “Assembly and Release of HIV-1 Precursor Pr55gag virus-like Particles from Recombinant Baculovirus-Infected Insect Cells”, Cell, vol. 59, pp. 103-112 (Oct. 6, 1989).
Felber, et al., “A Quantitative Assay for HIV-1 Based on Trans-Activiation”, Sci., vol. 239, pp. 184-187 (Jan. 8, 1988).
Coben, “A New Goal: Preventing Disease, Not Infection”, Sci., vol. 262, pp. 1820-1821 (Dec. 17, 1993).
Shafferman, et al., “Prevention of transmission of simian immunodeficiency virus from vaccinated macaques that developed transient virus infection following challenge”, Vac., vol. 11, Issue 8, pp. 848-853 (1993).
Colombo, et al., “Granulocyte Colony-stimulating Factor Gene Transfer Supresses Tumorigenicity of a Murine Adenocarcinoma In Vivo”, J. Exp. Med., vol. 173, pp. 889-897 (Apr. 1991).
Chan, et al., “Induction to Interferon γ Prodcution by Natural Killer Cell stimulatory Factor: Characterizationof the Responder Cells . . . ”, J. Exp. Med., vol. 173, pp. 869-879 (Apr. 1991).
Philip, et al., “In Vivo Gene Delivery”, J. Bio Chem., vol. 268, No. 22, pp. 16087-16090 (Aug. 5, 1993).
Novagen, pCITE™0 System Protocols, 565 Science Dr., Madison, WI 53711.
Viral Testing System Corp., Catalog showing availability of IAM 41-2F5.
Davis, et al., “DNA-based immunization induces continuous secretion of hepatitis B surface antigen and high levels of circulating antibody”, J. Exp. Med., vol. 173, pp. 889-897 (Apr. 1991).
Dubensky, et al., “Direct transfection of viral and plasmid DNA into the liver or spleen of mice”, Proc. Natl. Acad. Sci. USA, Genetics, vol. 81, pp. 7529-7533 (Dec. 1984).
Seeger, et al., “

Affiliated with

Also associated with

Rating

Coordinate in vivo gene expression does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Coordinate in vivo gene expression, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Coordinate in vivo gene expression will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3665184